Affibody has announced that the first patients have been dosed in a clinical basket study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification of HER2-status in solid tumors.
ABY-025 is based on an Affibody molecule that binds strongly to HER2 – a cell surface protein implicated in several forms of cancer. The high affinity and rapid clearance of ABY-025 from blood and normal tissue allows HER2 assessment within hours, states the company.
“This marks an important step in the ABY-025 program as we are now demonstrating use in gastroesophageal cancer,” says Fredrik Frejd, Professor and Chief Scientific Officer of Affibody. “We appreciate for our close collaboration with the leading clinical experts at Karolinska Institutet and Karolinska University Hospital and believe that the study results will pave the way for our therapeutic candidate ABY-271 in this patient population.”
The aim of the trial, which is part of Affibody’s radiopharmaceutical program, is to investigate 68Ga-ABY-025 for non-invasive quantification of HER2 status in solid tumors. Results from a cohort with breast cancer patients with low HER2 expression have recently been published. The trial now continues with the inclusion of additional patients with gastroesophageal cancer.
Photo of David Bejker: Affibody
